Novo Nordisk ® Clinical milestones 1 Regulatory milestones 1 H1 2023 H2 2023 EU/US/CN submission Phase 3 results Phase 2 results Phase 3a initiation Phase 1 results Phase 4 results ✓ Phase 3b initation Phase 3 results Phase 1/2 results Phase 3b results Phase 1 results EU/US/JP decision (GHD) EU submission (HAwI/HBwI) US/JP decision(HAwI/HBwI) Phase 3b initiation d States; EU: European Union; JP: Japan, CVOT: Cardiovascular Outcomes Trial; GHD: Growth Hormone Deficiency; HFpEF: Heart
Download PDF file